To characterize the pathogenicity of the EDMs, we investigated the associations of POLE variants with the clinical outcomes of the patients, their influences in chemosensitivity, cell cycle transition, and metastatic abilities of endometrial cancer cell lines, as well as the polymerase and exonuclease activities of the recombinant Polε mutants. This evidence concerns the gene POLE and endometrial cancer.